Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
AssigneesThe General Hospital Corporation, Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
InventorsAnthony H. Cincotta, Albert H. Meier, John M. Wilson
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for improving various aberrant metabolic indices in mammals including humans by administration of muscarinic (particularly M1) receptor antagonists alone or in combination with prolactin inhibiting compounds. Preferably the administration takes place at a predetermined time (or, if a combination of muscarinic receptor antagonist and prolactin inhibitor is used, at different predetermined times) during a 24-hour period when the administration is effective (or its effect more pronounced). The invention has application in the treatment of lipid and glucose metabolism disorders.
Claims15
A method for altering lipid metabolism in a vertebrate subject in need of such treatment comprising administering to said subject an amount of a muscarinic receptor antagonist selective for the M1 muscarinic receptor, said administration taking place at a predetermined time during a 24-hour period, said time and said amount being effective to accomplish at least one of:
- decreasing hyperlipoproteinemia, decreasing triglycerides, reducing body fat stores, and increasing the ratio of high-density to low-density lipoproteins in said subject.
A method for regulating lipid metabolism in a vertebrate subject in need of such treatment comprising administering to said subject an amount of a muscarinic receptor antagonist selective for the M1 muscarinic receptor, and an amount of a prolactin inhibitor, said amounts in combination being effective to accomplish at least one of decreasing hyperlipoproteinemia, decreasing triglycerides, reducing body fat stores, and increasing the ratio of high-density to low-density lipoproteins in said subject.
A method for altering lipid metabolism in a vertebrate animal or human subject in need of such treatment comprising administering to said subject an amount of a muscarinic receptor antagonist selective for the M1 muscarinic receptor, said amount being effective to accomplish at least one of:
- decreasing hyperlipoproteinemia, decreasing triglycerides, and increasing the ratio of high-density to low-density lipoproteins in said subject.
Dependencies are inferred from the claim text.